Cancer phospholipidome

摘要

In general, the present invention relates to identification of lipidome biomarkers for cancer analysis and it provides prognostic and predictive methods and kits for cancer diagnosis and subtyping and for diagnosing and/or predicting the evolution of a tumor and its response to lipid metabolism-targeted or other types of therapy in a subject, by making use of phospholipid (PL) profiling, wherein changes in the combined acyl chain length of intact body fluid-derived or tumor-derived phospholipid species is indicative of an elongation phenotype.

主权项

1. An in vitro method for subtyping a tumor in a human subject, said method comprising:
obtaining a tumor sample from said subject; isolating intact phospholipid species in at least one head group class from said tumor sample; determining a relative expression level of said intact phospholipid species in said at least one head group class in said tumor sample versus a normal sample using mass spectrometry (MS); and comparing changes in the relative expression level of phospholipid species having a same saturation level but different acyl chain lengths within said at least one head group class, to subtype said tumor; wherein a relative increase in longer chain phospholipid species compared to shorter chain phospholipid species within a head group class having the same saturation level is indicative of a tumor having an aggressive elongation phenotype, and wherein the shorter chain phospholipid species are phospholipid species with the same head group and equal number of unsaturations but with shorter than average (combined) acyl chain lengths selected from the group consisting of PC30:0, PC32:1, PC34:1, PC32:2, PC34:2, PC34:3, PC36:4, PC36:5, PC38:6; PE32:1, PE34:1, PE34:2, PE36:3, PE36:4, PE36:5, PE38:6, PE38:7, PE40:8, PS34:1, PS36:1, PS34:2, PS36:3, PS36:4, PS38:4, PS38:5, PS38:6 PS40:7; PI32:0, PI34:0, PI30:1, PI34:2, PI36:3, PI36:4, PI38:5 and PI38:6.